Abstract
Carbogen and nicotinamide have been evaluated in a phase II study as hypoxia-modifying agents during radical radiotherapy for bladder cancer using a standard daily 20-fraction schedule. Three groups of patients have received (a) nicotinamide alone, given orally in a dose of 80 mg kg(-1) daily with 52.5 Gy in 20 fractions over 4 weeks, (b) carbogen alone, with 50 Gy in 20 fractions over 4 weeks, and (c) carbogen and nicotinamide, with 50-52.5 Gy in 20 fractions over 4 weeks. Ten patients were treated in each group. All patients completed carbogen and radiotherapy as prescribed, but only 45% completed daily nicotinamide over the 4-week treatment period. The end points of this study were acute bowel and bladder morbidity and local control at cystoscopy 6 months after treatment. An expected level of acute bowel and bladder morbidity was seen that reverted to normal in most patients by 12 weeks with no difference between the three treatment groups. Complete response rates at 6 months were seven out of ten (100%) in the nicotinamide alone group, nine out of ten (90%) in the carbogen alone group and seven out of ten (70%) in the carbogen and nicotinamide group. It is concluded that carbogen and nicotinamide may improve the results of daily fractionated radiotherapy in bladder cancer and that further evaluation is required.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hoskin, P., Saunders, M., Phillips, H. et al. Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy. Br J Cancer 76, 260–263 (1997). https://doi.org/10.1038/bjc.1997.372
Issue Date:
DOI: https://doi.org/10.1038/bjc.1997.372
This article is cited by
-
Trimodale Therapie des muskelinvasiven Blasenkarzinoms – eine äquivalente Alternative zur Operation im lokalisierten Tumorstadium?
Die Onkologie (2022)
-
Molecular landmarks of tumor hypoxia across cancer types
Nature Genetics (2019)
-
Therapeutic options to overcome tumor hypoxia in radiation oncology
Clinical and Translational Imaging (2017)
-
GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON
British Journal of Cancer (2003)
-
Applications of Magnetic Resonance in Model Systems: Tumor Biology and Physiology
Neoplasia (2000)